News - Organon
WEBAug 6, 2024 · News. Browse our latest press releases to find more about Organon’s latest news.
Organon to Acquire Dermavant including its Innovative …
WEB1 day ago · VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. JERSEY CITY, N.J., September 18, 2024 – Organon (NYSE: OGN), a global healthcare company with a mission to improve ...
Organon makes $1.2bn play for Roivant’s immuno-dermatology …
WEB19 hours ago · In this article: Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the ...
Organon & Co. (OGN) Latest Stock News & Headlines - Yahoo …
WEBGet the latest Organon & Co. (OGN) stock news and headlines to help you in your trading and investing decisions.
Organon Reports Results for the Fourth Quarter and Full Year …
WEBDec 31, 2023 · Total revenue was $6.3 billion for full year 2023, an increase of 1% as-reported and an increase of 3% ex-FX, compared with the full year 2022. Women’s Health revenue increased 2% as-reported and 3% ex-FX for full year 2023 compared with 2022.
Organon (OGN) Outperforms Broader Market: What You Need to …
WEBSep 13, 2024 · Organon (OGN) ended the recent trading session at $20.47, demonstrating a +0.89% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.54% ...
Assessing Organon’s Strategic Acquisition of ... - Markets Insider
WEB1 day ago · Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women’s health, biosimilars, and ...
Roivant's Sale Of Dermavant To Organon: Win-Win In Atopic …
WEB13 hours ago · From a valuation perspective, ROIV will receive up to $1.2 billion from its Dermavant sale to OGN. However, only $175.0 million is an upfront cash payment, and the rest is contingent on milestones ...
Roivant dermatology subsidiary to be acquired by Organon
WEB2 days ago · Dive Brief: Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion in potential additional payments if certain milestones are hit. With the acquisition, Organon will gain Dermavant’s cream called Vtama, which was approved in 2022 to treat plaque psoriasis.
Organon Reports Results for the First Quarter Ended March 31, 2024
WEBMar 31, 2024 · Women’s Health revenue increased 11% on an as-reported basis, and increased 12% ex-FX in the first quarter of 2024 compared with the first quarter of 2023 primarily driven by 34% ex-FX growth in Nexplanon® (etonogestrel implant).
Skip to content